Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB878,5879,5-0,23
PKN73,5473,680,22
Msft-1,99
Nokia5,0635,0981,36
IBM1,66
Daimler AG85,1985,22-1,07
PFE2,32
04.12.2021 0:39:00
Indexy online
AD Index online
select
AD Index online
 

  • 30.11.2021 9:11:18
Hybrigenics (ALHYG.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
0,1376 -0,79 0,00 1
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 04.12.2021
Popis společnosti
Obecné informace
Název společnostiHybrigenics SA
TickerALHYG
Kmenové akcie:Ordinary Shares
RICALHYG.PA
ISINFR0004153930
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2017 17
Akcie v oběhu k 31.12.2020 233 769 740
MěnaEUR
Kontaktní informace
Ulice3-5 impasse Reille
MěstoPARIS
PSČ75014
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 158 103 800
Fax33158103849

Business Summary: Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2020,Hybrigenics SA revenues decreased from EUR235K to EUR0K.Net loss applicable to common stockholders decreased 56% toEUR327K. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Lower net loss reflects Other Purchases &External Charges decrease of 71% to EUR236K (expense),Personnel Costs decrease of 69% to EUR178K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 04.12.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardAlain Munoz7201.07.201501.07.2015
Chief Executive Officer, DirectorRemi Delansorne5315.10.200701.01.2004
Chief Financial OfficerGuillaume Floch44
Chief Executive Officer of Hybrigenics ServicesEtienne Formstecher3908.01.2014
Senior Director, Head of Clinical Research and DevelopmentJean-Francois Dufour-Lamartinie-01.01.2006